Skip to main content
. 2022 Mar 2;13:851089. doi: 10.3389/fphar.2022.851089

FIGURE 3.

FIGURE 3

SLC35B4 stabilizes c-Myc via O-GlcNAc modification. (A,B) Relative mRNA expression levels of c-Myc in 7703 (A) and HepG2 (B) cells with SLC35B4 knockdown. N = 3. Data are presented as mean ± SD. n.s., non-significant. (C) The protein levels of c-Myc in 7703 (upper) and HepG2 (bottom) cells with SLC35B4 knockdown. The relative protein levels are indicated. (D) The protein levels of c-Myc protein in 7703 (upper) and HepG2 (bottom) cells after CHX treatment. (E,F) Quantification of the protein levels of c-Myc in 7703 (E) and HepG2 (F) cells with or without SLC35B4 knockdown at different time points after CHX treatment. The relative protein levels are indicated. (G) The O-GlcNAcylation of c-Myc after SLC35B4 knockdown. c-Myc in 7703 (left) and HepG2 (right) cells with or without SLC35B4 knockdown was immunoprecipitated and the levels of the O-GlcNAcylation were detected with anti-O-GlcNAc antibody. The relative levels of O-GlcNAcylated versus total c-Myc are indicated.